ESMO 18th World Congress on Gastrointestinal Cancer
29 June – 2 July 2016 | Barcelona, Spain

Congress Chairs: Mario Dicato, MD,
Eric Van Cutsem, MD, PhD and Josep Tabernero, MD, PhD

Wednesday, 29 June 2016

Session I: Opening, Selected Abstracts, and Lectures on Nutrition

Chairs: Mario Dicato, MD, Eric Van Cutsem, MD, PhD and Josep Tabernero, MD, PhD

14:50 Presentation of selected abstracts

The influence of multidisciplinary teams on diagnosis and treatment
Yara Basta, et al., O-001

Safety and efficacy of cobimetinib (cobi) and atezolizumab (atezo) in a Phase 1b study of metastatic colorectal cancer (mCRC)
Johanna Bendell, et al., LBA-01

15:10 Opening Lecture: Pitfalls in imaging for liver tumors
Jens Ricke, MD

15:30 Nutritional support in gastrointestinal cancer:

Cancer cachexia and sarcopenia in GI cancer: Mechanism and ways to interfere with it
Florian Strasser, MD, ABHPM

Does peri-operative nutritional support improve the outcome in GI cancer patients?
Dileep Lobo, MD

Session II: Cancer of the Pancreas and Bile Ducts

Chairs: Jordan D. Berlin, MD and Michel Ducreux, MD, PhD

16:10 Are we making progress in understanding the biology of pancreatic cancer?
Giampaolo Tortora, MD, PhD
16:30  Screening in familial pancreatic cancer  
*Pascal Hammel, MD, PhD*

16:40  **Presentation of selected abstract**

Utilization and trends in palliative therapy for stage IV pancreatic adenocarcinoma patients: A U.S. population based study  
*Audrey Kulaylat, et al., O-002*

16:55  **Controversy Debate 1:** Is it justified to move from adjuvant to neo-adjuvant treatment?  
**Yes**  
*Jordan D. Berlin, MD*

**No**  
*Thomas Seufferlein, MD*

17:25  Are we making progress in surgery of the pancreas?  
*Massimo Falconi, MD*

17:45  **Presentation of selected abstracts**

Long-term outcome from the SCALOP trial: A multi-centre randomized phase II trial of Gemcitabine or Capecitabine-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC)  
*Somnath Mukherjee, et al., O-003*

Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine  
*Richard Hubner, et al., O-004*

18:05  Deciding the initial chemotherapy for patients with metastatic pancreatic cancer  
*Eileen O’Reilly, MD*

18:25  New agents/strategies on the horizon in pancreatic cancer  
*Margaret A. Tempero, MD*
Thursday, 30 June 2016

Session III: Meet the Expert Concurrent Presentations
Parallel with Session IV: Clinical Trials Methodology and Endpoints

8:00   Anal cancer
       Cathy Eng, MD and Karin Haustermans, MD, PhD

Cholangiocarcinoma and gall bladder cancer
       Michel Ducreux, MD, PhD

Teaching Lecture: Thrombosis in cancer (Novel oral anticoagulants included)
       Mario Dicato, MD

Challenges and limitations in rectal cancer surgery
       Andre D’Hoore, MD

Recent advances in the management of GIST
       John R. Zalcberg, MD, PhD, MBBS

Implementing molecular testing in clinical practice: How to test, what to test and when?
       Quality control of testing
       Han van Krieken, MD

Session IV: Clinical Trials Methodology and Endpoints
Parallel with Session III: Meet the Expert Concurrent Presentations
Chairs: Axel Grothey, MD and Alberto Sobrero, MD

8:00   Does response evaluation still matter in the era of targeted agents? Does it predict for outcome?
       Volker Heinemann, MD

8:20   How can we evaluate best the activity of immune therapies in GI cancer?
       Beyond RECIST 1.1.: Role of irRECIST, PET/CT and paired biopsies to evaluate the activity of immune therapies in GI cancer.
       Guillem Argilés, MD

View Slides
8:40  How relevant is tumor regression grade evaluation in rectal cancer?
Iris Nagtegaal, MD, PhD

9:10  The ESMO and ASCO clinical benefit scales: Do they impact on our practice?
Alberto Sobrero, MD

Session V: Esophageal and Gastric Cancers
Chairs: Karin Haustermans, MD, PhD and Florian Lordick, MD, PhD

9:00  Controversy Debate 2: Selecting optimal treatments for esophagus cancer
Which patients with esophageal cancer should be operated?
David Cunningham, MD

Which patients with esophageal cancer should not be operated?
George Hanna, MD

9:40  What is the most optimum perioperative treatment in esophageal cancer
David H. Ilson, MD, PhD

10:00 Gastric carcinogenesis of gastric cancer through the eyes of a pathologist
Fátima Carneiro, MD, PhD

10:20 Presentation of selected abstract
Comparative molecular analyses of esophageal adenocarcinoma, esophageal squamous cell carcinoma, and gastric adenocarcinoma, and impact of molecular profile on outcome
Mohamed Salem, et al., O-005

10:30 Keynote Lecture 1: Unraveling the taxonomy in gastric cancer
Adam Bass, MD
Session VI: Gastric Cancer  

Chairs: David H. Ilson, MD, PhD and Philippe Rougier, MD, PhD

11:30  Presentation of selected abstract

A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study  
Marcel Verheij et al., LBA-002

11:40  Controversy Debate 3: Neo-adjuvant/Adjuvant treatment in gastric cancer

The EU view  
Marc Ychou, MD

The US view  
Manish A. Shah, MD

The surgical point of view  
William H. Allum, MD, FRCS

12:20  Presentation of selected abstracts

Survival impact of histology for resectable gastric cancer: A multicenter U.S. observation study  
Erin Greenleaf, et al., O-006

Biomarker analyses of second-line Ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study  
Eric Van Cutsem, et al., O-007

12:40  Targeting HER 2 and angiogenesis in gastric cancer: What is the impact?  
Andrés Cervantes, MD, PhD

12:55  New agents on the horizon in gastric cancer  
Florian Lordick, MD, PhD
**Session VII: Rare Tumors: Neuroendocrine Tumors, Gastrointestinal Stromal Tumors and Anal Cancer**

*Chairs: Rachel Riechelmann, MD, PhD and John R. Zalcberg, MD, PhD, MBBS*

15:10 **Presentation of selected abstracts**

Impact of chromogranin A, grade, and mitotic rate in small, non-functional pancreatic neuroendocrine tumors: A U.S population based study
*Katelin Mirkin, et al., O-008*

NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate
*Jonathan Strosberg, et al., O-009*

15:30 **Tandem Talk 1: Imaging in NET**

Contribution of CT and MRI
*Timm Denecke, MD*

[Watch Presentation] [View Slides]

Contribution of isotopic scanning
*Christophe Deroose, MD, PhD*

[Watch Presentation] [View Slides]

16:00 **Tandem Talk 2: The approach for gastric NETs**

The pathologist's contribution
*Guido Rindi, MD, PhD*

The clinician's contribution
*Bertram Wiedenmann, MD*

[Watch Presentation] [View Slides]

16:30 Developing a therapeutic algorithm in small bowel NETs
*Jaume Capdevila, MD*

[Watch Presentation] [View Slides]

16:50 Which new agents on the horizon in NET?
*James C. Yao, MD*
**Session VIII: Liver Malignancies**

*Chairs: Philippe Rougier, MD, PhD and Chris Verslype, MD, PhD*

**17:40**

**Presentation of selected abstract**

Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, randomized phase 3 RESORCE trial  
Jordi Bruix, et al., LBA-03

Discussant

Jean-Luc Raoul, MD, PhD

**18:10**

**Tandem Talk 3: Hepatocellular carcinoma**

Medical treatment  
Jordi Bruix, MD, PhD

Locoregional Treatment  
Chris Verslype, MD, PhD

**18:40**

**New targets and new agents in HCC**  
Eric Raymond, PhD

Friday, 1 July 2016

**Session IX: Meet the Expert Concurrent Presentations**

*Parallel with Session X: Presentation of Selected Abstracts: Colorectal Cancer, Session XI: Presentation of Selected Abstracts: Miscellaneous and Session XII: ESMO Session: Focus on Young Medical Oncologists*

**8:00**

**Carcinoma of unknown origin**  
Nicholas Pavlidis, MD, PhD, FRCP

Teaching the basics of statistics  
Ulrich Güller, MD, MHS

**Treatment of elderly patients with GI cancer**  
Demetris Papamichael, MB, BS, FRCP
Workshop: Liver surgery for metastatic CRC

Thomas Gruenberger, MD

Session X: Presentation of Selected Abstracts - Colorectal Cancer
Parallel with Session IX: Meet the Expert Concurrent Presentations, Session XI: Presentation of Selected Abstracts: Miscellaneous

Chairs: Axel Grothey, MD and Bernard Nordlinger, MD

8:00

Presentation of selected abstracts

Prognosis of lung metastases in patients with metastatic colorectal cancer: An ARCAD meta analysis
Einat Shacham-Shmueli, et al., O-012

A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC)
Filippo Pietrantonio, et al., O-013

Evaluation of depth of response within a volumetric model in patients with metastatic colorectal cancer: Results of the SIRFLOX study
Volker Heinemann, et al., O-014

Association between depth of response (DpR) and survival outcomes in RAS-wild-type (wt) patients with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab once-every-2-weeks in the APEC study
Ann-Lii Cheng, et al., O-015

Discussant
Dan Sargent, PhD

An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: Compliance and safety of the phase III Japanese ACHIEVE trial
Tetsuya Eto, et al., O-010
Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO

Carlotta Antoniotti, et al., O-011

Discussant
Claus-Henning Köhne, MD

Session XI: Presentation of Selected Abstracts - Miscellaneous
Parallel with Session IX: Meet the Expert Concurrent Presentations, Session X: Presentation of Selected Abstracts: Colorectal Cancer
Chairs: Florian Lordick, MD, PhD and Rachel Riechelmann, MD

8:00

Presentation of selected abstracts
A prognostic marker for colorectal cancer: Combining analyses of ploidy and stroma
Susan Fotheringham, et al., O-016

Can single nucleotide variants in TGFBR1 and SMAD7 modify colorectal screening recommendations?
G.A.T. Mahon, et al., O-017

Clinical application of targeted next generation sequencing for colorectal cancer patients: A multicentric Belgian experience
Quitterie Fontanges, et al., O-018

Discussant
Heinz-Josef Lenz, MD

The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results
Antoine Adenis, et al., LBA-04

IMAB362: A novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer
Salah-Eeddin Al-Batran, et al., LBA-06
Discussant
Florian Lordick, MD, PhD

Session XII: ESMO Session: Focus on Young Medical Oncologists
Parallel with Session IX: Meet the Expert Concurrent Presentations, Session X: Presentation of Selected Abstracts: Colorectal Cancer and Session XI: Presentation of Selected Abstracts: Miscellaneous
Chairs: Guillem Argiles, MD and Josep Tabernero MD, PhD

Mentorship:
8:00 Building a solid CV in the molecular oncology era. Balance between bench and bedside. 
Eduardo Vilar Sanchez, MD, PhD
View Slides
8:20 How to find a good mentor in GI oncology 
Richard M. Goldberg, MD

Scientific:
8:50 Clinical implications of transcriptional subtyping in mCRC 
Rodrigo Dienstmann, MD
View Slides
9:10 Beyond NGS, towards functional prescreening models in therapeutic decisions in cancer. 
Loredana Vecchione, MD, PhD

Session XIII: Prevention of GI Cancer
Chairs: Nadir Arber, MD, MHA, MSC and Wolff Schmiegel, MD, PhD, AGAF
9:05 Hereditary colorectal cancer and gastric cancer 
Judith Balmaña, MD, PhD
Watch Presentation View Slides
9:25 Does advanced imaging help in the detection of CRC? 
Nadir Arber, MD, MHA, MSC
Watch Presentation View Slides
9:45 What is the impact of population screening for CRC? 
Monique Van Leerdam, MD, PhD
Watch Presentation View Slides
10:05  Keynote Lecture 2: The gut microbiome and cancer

Jeroen Raes, PhD

Session XIV: Multimodality Therapy for Rectal Cancer

Chairs: Julio Garcia-Aguilar, MD, PhD and Robert Glynne-Jones, MBBS, FRCR, FRCP

11:05  MRI in rectal cancer staging is mandatory

Gina Brown, MD, FRCR

Watch Presentation  View Slides

11:25  Organ preservation in rectal cancer: How and for whom?

Andre D’Hoore, MD, PhD

Watch Presentation  View Slides

11:40  Advances and challenges in the surgical treatment of locally advanced rectal cancer

Julio Garcia Aguilar, MD, PhD

Watch Presentation  View Slides

11:55  Presentation of selected abstracts

Outcome results of STAR-01, a randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer.

Sara Lonardi, et al., O-019

Impact of surgical site experience on treatment outcomes of fixed-cT3 and cT4 rectal cancer patients in phase III study comparing preoperative radiochemotherapy and short-course radiotherapy with consolidation chemotherapy (Polish-II study)

Lucjan Wyrwicz, et al., O-020

Tailored strategy for locally-advanced rectal carcinoma: Preliminary results of a phase II multicenter trial (GRECCAR 4)

Philippe Rouanet, et al., O-021

12:25  Discussant

Robert Glynne-Jones, MBBS, FRCR, FRCP

12:40  Tumor Board 1: Challenging cases

Andrés Cervantes, MD, PhD and Karin Haustermans, MD, PhD

Watch Presentation  View Slides
Session XV: Immune Mechanisms and Immune Therapy in GI Cancer
Chair: Howard Hochster, MD

15:00  **Keynote Lecture 3:** Understanding the relevant immune mechanisms in GI cancer
Aurélien Marabelle, MD, PhD

15:30  Immune therapy in metastatic CRC
Julien Taieb, MD, PhD

15:45  Immune therapy in non-metastatic CRC
Markus Möhler, MD, PhD

16:00  **Presentation of selected abstract**
A multi-institutional phase 2 study of single agent nivolumab in previously treated metastatic squamous cell carcinoma of the anal canal (SCCA)
Cathy Eng, et al., O-022

16:10  **Keynote Lecture 4:** The BRAF pathway in CRC?
Scott Kopetz, MD, PhD, FACP

Session XVI: Pathology and Molecular Biology in CRC
Chairs: Fortunato Ciardiello, MD, PhD and Han van Krieken, MD

17:10  How to improve the diagnosis of stage III colon cancer?
Han van Krieken, MD

17:30  Molecular classification of colon cancer: Impact on clinical practice
Sabine Tejpar, MD, PhD

17:50  Are gene signatures ready for use in the selection of patients for adjuvant treatment?
Ramon Salazar, MD

18:10  Current status and perspectives on liquid biopsy in mCRC
Alberto Bardelli, MD
Session XVII: Highlights of ASCO and ESMO GI Abstracts  
*Chairs: Fortunato Ciardiello, MD, PhD and Han van Krieken, MD*

18:30  **Selected Abstracts:** Highlights of poster discussions and posters at ESMO GI  
*Roberto Labianca, MD*  
[Watch Presentation]  [View Slides]

18:45  **Selected Abstracts:** Highlights from ASCO 2016  
*Rachel Riechelmann, MD, PhD*

Saturday, 2 July 2016

Session XVIII: Keynote Lecture: Health Economics and Cost  
*Chair: Mario Dicato, MD*

8:30  **Keynote Lecture 5:** Health economics and cost  
*Alexandru E. Eniu, MD, PhD*

Will availability of drugs become an issue? The physician’s and the payer’s perspective  
*Paul Cornes, MD*  
[Watch Presentation]  [View Slides]

Session XIX: Colorectal Cancer  
*Chairs: Josep Tabernero, MD, PhD and Eric Van Cutsem, MD, PhD*

9:30  **Controversy Debate 4:** Treatment algorithms in metastatic CRC  
*Eric Van Cutsem, MD, PhD*  
[Watch Presentation]  [View Slides]

The ESMO guidelines on metastatic CRC  
NCCN guidelines  
*Axel Grothey, MD*  
[Watch Presentation]  [View Slides]

Asian guidelines  
*Takayuki Yoshino, MD*  
[Watch Presentation]  [View Slides]

10:55  **How to improve the adjuvant treatment of colon cancer?**  
*Aimery de Gramont, MD*  
[Watch Presentation]  [View Slides]
11:15 **Presentation of selected abstracts**

Observational data outcomes of chemotherapy backbone for MSI-high metastatic colorectal cancer in molecular epidemiology of colorectal cancer study in Isreal
*Katerina Shulman, et al., O-023*

Circulating tumor DNA extended RAS mutational analysis as a surrogate of mutational status of tumor samples in metastatic colorectal cancer and its impact on patient selection for anti-EGFR therapy.
*Julieta Grasselli, et al., O-024*

Discussant
*Fortunato Ciardiello, MD, PhD*

First-line FOLFOX-4 ± cetuximab in Chinese patients with RAS-wild-type (wt) metastatic colorectal cancer (mCRC): The open-label, randomized phase 3 TAILOR trial
*Tianshu Liu, et al., LBA-05*

Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): Phase 2 results
*Josep Tabernero, et al., O-026*

A pivotal phase 3 Trial of MABp1 in advanced colorectal cancer
*Tamas Hickish, et al., O-027*

Discussant
*Dirk Arnold, MD, PhD*

12:40 **Is tumor location relevant in the treatment decision in metastatic disease?**
*Heinz-Josef Lenz, MD*

14:45 **Session XX: The Future of Surgery**
*Chairs: Mario Dicato, MD and Bernard Nordlinger, MD*

**Keynote Lecture 6:** Robotic surgery: Is it becoming a reality in GI cancer?
*Philippe Rouanet, MD*
Session XXI: Liver and Peritoneal Metastases

*Chairs: Mario Dicato, MD and Bernard Nordlinger, MD*

15:15 **Recommendation on the management of synchronous/metachronous liver metastases**

*René Adam, MD, PhD*

15:45 **Tandem Talk: Liver directed therapy in incurable mCRC: When and how?**

*Stereotactic radiotherapy*

*Francoise Mornex, MD, PhD*

Radio- or chemoembolization

*Harpreet Wasan, MBBS, FRCP*

16:15 **Treatment of surgically resectable colorectal peritoneal metastases**

*Marcello Deraco, MD*

16:35 **Session XXII: Report on Expert Discussion**

*Chairs: Mario Dicato, MD and Bernard Nordlinger, MD*

16:35 **Presentation of outcome of expert discussion:**

*Mario Dicato, MD, Eric Van Cutsem, MD, PhD and Josep Tabernero, MD, PhD*